0000000000639460

AUTHOR

Rossana Casaretti

showing 3 related works from this author

Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Onc…

2009

Purpose: This phase II trial assessed the tolerability and efficacy of a triplet of oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer. Methods: Patients with unresectable or metastatic gastric cancer, unexposed to palliative chemotherapy, received oxaliplatin 85 mg/m 2 iv and irinotecan 150 mg/m2 iv on day 1, 6S-folinic acid 250 mg/m2 iv and fluorouracil 750 mg/m2 iv on day 2, every 2 weeks. Response rate (RR) was assessed after a minimum of four cycles, and treatment continued up to 12 cycles. Results: Sixty-three patients were treated, with a median of eight (range 1-12) cycles/patient. Two complete and 19 partial responses were registered (RR 33% [95% CI, …

OncologyMaleCancer ResearchOrganoplatinum CompoundsAntimetabolitesSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntidotesLeucovorinKaplan-Meier EstimateToxicologyPhytogenicAntineoplastic Combined Chemotherapy Protocols80 and overMedicinePharmacology (medical)Stomach cancerTomographyAged 80 and overMiddle AgedAntineoplasticMagnetic Resonance ImagingX-Ray ComputedOxaliplatinOncologyFluorouracilFemaleFluorouracilmedicine.drugAdultmedicine.medical_specialtyAntimetabolites AntineoplasticAntineoplastic AgentsNeutropeniaAdenocarcinomaIrinotecanFolinic acidStomach NeoplasmsTomography X-Ray Computed; Male; Aged 80 and over; Antimetabolites Antineoplastic; Middle Aged; Kaplan-Meier Estimate; Camptothecin; Survival Analysis; Female; Fluorouracil; Adenocarcinoma; Leucovorin; Humans; Organoplatinum Compounds; Antineoplastic Agents; Stomach Neoplasms; Magnetic Resonance Imaging; Antidotes; Blood Cell Count; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Agents Phytogenic; Aged; AdultInternal medicineHumansAgedPharmacologyChemotherapybusiness.industryGastric cancerFluorouracilIrinotecan OxaliplatinTriplet regimenmedicine.diseaseAntineoplastic Agents PhytogenicSurvival Analysisdigestive system diseasesOxaliplatinBlood Cell CountIrinotecanCamptothecinbusinessTomography X-Ray ComputedFebrile neutropeniaCancer chemotherapy and pharmacology
researchProduct

Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Ita…

2005

Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma. A total of 318 cycles were administered, with a median of 8 (range, 4-12) cycles per patient. Response rate (RR) was 45% (95% confidence interval (CI), 29%-62%), with 7 complete responses and 10 partial responses; furthermore, 12 patients showed a stable disease, so that a disease control was achieved in 29 (76%) patients. RR was greater among patients with performance status 0 (52%), without weight loss (52%), younger than 65 years (50%), and previou…

AdultMaleAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyLung NeoplasmsOrganoplatinum CompoundsColorectal cancerPhases of clinical researchAntineoplastic AgentsToxicologyDeoxycytidineGastroenterologyDisease-Free SurvivalCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansPharmacology (medical)CapecitabinePeritoneal NeoplasmsAgedAged 80 and overPharmacologyPerformance statusbusiness.industryCarcinomaLiver NeoplasmsMiddle Agedmedicine.diseaseOxaliplatinSurgeryOxaliplatinRegimenItalyOncologyFluorouracilLymphatic MetastasisFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugCancer Chemotherapy and Pharmacology
researchProduct

Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal ca…

2006

Oxaliplatin (OXA) and irinotecan (IRI) are active drugs for metastatic colorectal cancer, their toxicity profiles are not overlapping, and both drugs have shown at least additivity with folinic acid-modulated 5-fluorouracil (5FU). We carried out this phase II study to assess the activity and toxicity of a biweekly regimen including OXA plus IRI on day 1, and levo-folinic acid (LFA) plus 5FU on day 2 (OXIRIFAFU) in pretreated patients with metastatic colorectal cancer. Forty-one patients, all previously treated with adjuvant and/or palliative 5FU-based chemotherapy (16 of them already exposed to IRI, OXA or both), were enrolled into this trial. On the basis of sensitivity to previous treatme…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerLeucovorinPhases of clinical researchIrinotecanDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisAgedPharmacologybusiness.industryMiddle Agedmedicine.diseasedigestive system diseasesSurgeryOxaliplatinIrinotecanOxaliplatinOncologyFluorouracilToxicityInjections IntravenousDisease ProgressionCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugAnti-cancer drugs
researchProduct